Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880521 | 0.77 | ALDH1A1 (0.62) | USP2HTTENPP2ALDH1A1LMNA | |
| SCHEMBL4882007 | 0.75 | ALDH1A1 (0.64) | USP2HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4882943 | 0.73 | ALDH1A1 (0.53) | USP2HTTENPP2ALDH1A1LMNA | |
| SCHEMBL4881785 | 0.70 | MEN1 (0.69) | USP2HTTENPP2ALDH1A1LMNA | |
| SCHEMBL29657133 | 0.67 | ALDH1A1 (0.69) | USP2HTTENPP2ALDH1A1MAPT | |
| SCHEMBL29438208 | 0.67 | HTT (0.72) | USP2HTTENPP2ALDH1A1MAPT | |
| SCHEMBL29739849 | 0.65 | HTT (0.77) | HTTENPP2ALDH1A1MAPTMEN1 | |
| SCHEMBL29656984 | 0.64 | ENPP2 (0.71) | USP2HTTENPP2ALDH1A1MAPT | |
| SCHEMBL29739754 | 0.63 | HTT (0.78) | HTTENPP2ALDH1A1MAPTMEN1 | |
| SCHEMBL19721050 | 0.63 | PARP1 (0.42) | USP2HTTALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1698335-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DISEASE IN WHICH MITOCHONDRIAL BENZODIAZEPINE RECEPTOR PARTICIPATES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | MTNR1A, GSR, NLN | USP2 4686/4885HTT 1199/4885ENPP2 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.